지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 저널정보
- 대한병리학회 Journal of Pathology and Translational Medicine Journal of Pathology and Translational Medicine 제47권 제2호
- 발행연도
- 2013.1
- 수록면
- 100 - 106 (7page)
이용수
초록· 키워드
오류제보하기
Mutations of the epidermal growth factor receptor (EGFR) are the strongest predictive factor for response to EGFR tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib. EGFR TKIs are approved in Korea as a first-line treatment for lung cancer patients with mutated EGFR. Rapid and accurate EGFR mutation testing is essential for patient selection and establishing targeted therapies with EGFR TKIs. Thus, a standard set of guideline recommendations for EGFR mutation testing suitable for the Korean medical community is necessary. In this article, we propose a set of guideline recommendations for EGFR mutation testing that was discussed and approved by the Cardiopulmonary Pathology Study Group of the Korean Society of Pathologists.
목차
등록된 정보가 없습니다.
참고문헌 (20)
참고문헌 신청
Cagle PT / 2012 / Advances in treatment of lung cancer with targeted therapy / Arch Pathol Lab Med 136 : 504 ~ 509
D’Angelo SP / 2011 / Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas / J Clin Oncol 29 : 2066 ~ 207
Fukuoka M / 2011 / Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel
Janku F / 2010 / Targeted therapy in non-small-cell lung cancer: is it becoming a reality? / Nat Rev Clin Oncol 7 : 401 ~ 414
Linardou H / 2009 / Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC / Nat Rev Clin Oncol 6 : 352 ~ 366
D’Angelo SP / 2011 / Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas / J Clin Oncol 29 : 2066 ~ 207
Fukuoka M / 2011 / Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel
Janku F / 2010 / Targeted therapy in non-small-cell lung cancer: is it becoming a reality? / Nat Rev Clin Oncol 7 : 401 ~ 414
Linardou H / 2009 / Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC / Nat Rev Clin Oncol 6 : 352 ~ 366
이 논문의 저자 정보
최근 본 자료
댓글(0)
0